B. Riley Comments on InfuSystem's Q2 Earnings (NYSE:INFU)

Key Points

• B. Riley has raised its Q2 2026 earnings per share estimate for InfuSystem to $0.10, up from a previous forecast of $0.06, maintaining a "Strong-Buy" rating on the stock.
• The consensus estimate for InfuSystem's full-year earnings is $0.15 per share, with B. Riley also projecting Q4 2026 earnings at $0.16 EPS.
• Institutional investors have shown increased interest in InfuSystem, with notable increases in stock holdings by firms like BNP Paribas Financial Markets and Wells Fargo & Company in the fourth quarter.

InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) - Equities research analysts at B. Riley lifted their Q2 2026 EPS estimates for InfuSystem in a research report issued to clients and investors on Tuesday, August 5th. B. Riley analyst A. Schock now expects that the company will earn $0.10 per share for the quarter, up from their previous estimate of $0.06. B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for InfuSystem's current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem's Q4 2026 earnings at $0.16 EPS.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of InfuSystem from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, May 14th. Roth Capital started coverage on shares of InfuSystem in a research note on Tuesday, July 22nd. They set a "buy" rating and a $12.00 target price for the company.

InfuSystem Stock Performance

Shares of INFU traded up $1.31 during mid-day trading on Thursday, hitting $8.83. 654,482 shares of the company's stock were exchanged, compared to its average volume of 157,035. InfuSystem has a fifty-two week low of $4.61 and a fifty-two week high of $9.97. The firm has a market capitalization of $185.57 million, a P/E ratio of 147.19 and a beta of 1.81. The business's 50 day moving average is $6.11 and its two-hundred day moving average is $6.18. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in INFU. Nuveen LLC purchased a new position in InfuSystem during the first quarter worth about $465,000. Minerva Advisors LLC raised its holdings in InfuSystem by 7.5% during the first quarter. Minerva Advisors LLC now owns 910,677 shares of the company's stock worth $4,899,000 after purchasing an additional 63,826 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in InfuSystem by 13.1% during the first quarter. Russell Investments Group Ltd. now owns 437,891 shares of the company's stock worth $2,356,000 after purchasing an additional 50,877 shares in the last quarter. American Century Companies Inc. purchased a new position in InfuSystem during the first quarter worth about $256,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in InfuSystem during the second quarter worth about $294,000. 71.13% of the stock is owned by hedge funds and other institutional investors.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.